Skip to main content
SpringerLink
Log in

Health Canada has endorsed important safety information on Gilenya [fingolimod],

  • News item
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Health Canada.GILENYA (fingolimod) - Stronger Safety Recommendations Regarding First-Dose Heart Monitoring and Use in Patients with Heart Conditions - For Health Professionals. Internet Document: [4 pages], 21 Aug 2012. Available from: URL: http://www.hc-sc.gc.ca/

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Health Canada has endorsed important safety information on Gilenya [fingolimod],. React. Wkly. 1417, 3 (2012). https://doi.org/10.2165/00128415-201214170-00007

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00128415-201214170-00007

Keywords

Search

Navigation